NPI: 1861469314 · DEERFIELD BEACH, FL 33441 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/03/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (SR DIRECTOR LICENSURE&CERTIFICATION) |
| NPI Enumeration Date | 03/03/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 13,031 | $1.48M |
| 2019 | 20,648 | $2.47M |
| 2020 | 21,443 | $2.79M |
| 2021 | 18,781 | $2.14M |
| 2022 | 8,535 | $1.32M |
| 2023 | 578 | $185K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 29,988 | 1,204 | $3.57M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 22,942 | 1,536 | $3.31M |
| J1270 | Injection, doxercalciferol, 1 mcg | 14,368 | 971 | $1.62M |
| A4657 | Syringe, with or without needle, each | 3,965 | 1,295 | $667K |
| J1756 | Injection, iron sucrose, 1 mg | 6,055 | 1,059 | $525K |
| 85048 | 1,274 | 784 | $151K | |
| 85041 | 1,275 | 784 | $151K | |
| 83970 | 819 | 526 | $101K | |
| 83550 | 725 | 481 | $85K | |
| 83540 | 725 | 481 | $85K | |
| 82728 | 579 | 382 | $73K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 205 | 89 | $30K |
| 82108 | 96 | 65 | $12K |